Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review
- PMID: 35871104
- DOI: 10.1016/j.blre.2022.100989
Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review
Abstract
Background The limited supply of universal plasma has resulted in transfusion of ABO incompatible plasma to patients. As the need to implement whole blood transfusion in pre-hospitals setting rises, the lowest cut-off for anti-A/anti-B that does not cause haemolysis remains unknown. In this first scoping review, we aimed to determine the lowest ABO titre and volume reported in the literature to cause haemolysis from ABO incompatible plasma transfusions (plasma, platelets, cryoprecipitate, and whole blood). Methods We searched several databases from inception to April 2022, including all study types. Three independent reviewers extracted and reviewed the data. Primary outcome was the anti-A and anti-B titre (measured by IgM or IgG) that resulted in measurable haemolysis following ABO incompatible plasma transfusion. Results We identified 5681 citations, of which 49 studies were eligible, reporting a total of 62 cases (34 adults, 14 children and 14 did not specify age). The methods for antibody measurement and antibody type (IgG or IgM) varied significantly between studies. Component volumes were poorly reported. The most common component responsible for the haemolysis was apheresis platelets followed by pooled platelets and whole blood. Most haemolytic cases reported were due to anti-A. The lowest anti-A titre reported to cause haemolysis (children and adults) was 32 (IgG), while for anti-B it was 512 (IgG and IgM) for adults, 16,384 for paediatrics (IgG and IgM) and 128 (IgM) in cases where the age was not specified. The lowest reported volume associated with haemolysis were 100 ml (adults) and 15 ml (children). Of the 62 15 (24%) died. Conclusion The lowest titre reported to cause haemolysis was an anti-A of 32. ABO mismatch plasma transfusion may be associated with significant mortality. There is a need to agree/standardise methods for ABO titration measurement internationally for plasma components and agree the lowest anti-A/anti-B titre for transfusing ABO mismatched plasma.
Keywords: ABO incompatible; Anti-A; Anti-B; Haemolysis; Plasma; Platelets; Titre; Transfusion; Volume.
Copyright © 2022. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest All authors declare no conflict of interests.
Similar articles
-
Comparison of ABO antibody titration, IgG subclasses and qualitative haemolysin test to reduce the risk of passive haemolysis associated with platelet transfusion.Transfus Med. 2020 Aug;30(4):317-323. doi: 10.1111/tme.12687. Epub 2020 Jun 2. Transfus Med. 2020. PMID: 32484285 Clinical Trial.
-
Severe acute haemolytic transfusion reaction secondary to a plasma incompatible group B platelet transfusion.Transfus Med. 2023 Apr;33(2):188-193. doi: 10.1111/tme.12938. Epub 2022 Nov 15. Transfus Med. 2023. PMID: 36380475
-
Delayed intravascular haemolysis following multiple asymptomatic ABO-incompatible red blood cell transfusions in a patient with hepatic failure.Vox Sang. 2008 Oct;95(3):232-5. doi: 10.1111/j.1423-0410.2008.01085.x. Vox Sang. 2008. PMID: 19121188
-
Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma.Transfusion. 2013 Jan;53 Suppl 1:114S-123S. doi: 10.1111/trf.12045. Transfusion. 2013. PMID: 23301963 Review.
-
ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.Transfus Apher Sci. 2010 Feb;42(1):83-8. doi: 10.1016/j.transci.2009.10.013. Epub 2010 Jan 19. Transfus Apher Sci. 2010. PMID: 20034854 Review.
Cited by
-
Associations between ABO non-identical platelet transfusions and patient outcomes-A multicenter retrospective analysis.Transfusion. 2023 May;63(5):960-972. doi: 10.1111/trf.17319. Epub 2023 Mar 30. Transfusion. 2023. PMID: 36994786 Free PMC article.
-
Chemotherapy plus therapeutic plasmapheresis with 4% human albumin solution in multiple myeloma patients with acute kidney injury: a prospective, open-label, proof-of-concept study.Ren Fail. 2024 Dec;46(1):2356708. doi: 10.1080/0886022X.2024.2356708. Epub 2024 May 27. Ren Fail. 2024. PMID: 38803220 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous